BIOTECH ASSISTANT / FIELD NOTES

WuXi AppTec reports nine-month 2026 results and raises full-year guidance

Company / institutional announcement · WuXi AppTec

Source published: · Event / reporting date: 2026-10-26

Site published: 2026-11-03 · Updated: 2026-11-03

Explore this article with AI

This source is linked automatically. Choose a question to get started.

Ask AI ↗

What changed

WuXi AppTec reported nine-month 2026 revenue of RMB 45.54 billion, up 38.6% year over year. Revenue from continuing operations rose 46.3%, and continuing-operations backlog reached RMB 76.74 billion, up 36.4%. The company also raised full-year guidance. Total-revenue and continuing-operations growth rates use different reporting scopes and should not be treated as interchangeable.

Why it may matter

The disclosures help track this company's operating momentum and order book, but do not establish an industry-wide recovery. Peer comparisons still require consistent periods, business scope, and accounting measures.

The interpretation above is analysis, not a conclusion attributed to the original source.

Read the original source ↗

Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections

China-listed CRO/CDMO

Related updates

Fresenius

Fresenius gains development options on up to 37 WuXi Biologics biosimilar candidates

Fresenius signed an exclusive development agreement with WuXi Biologics providing access to up to 37 biosimilar candidates over the next decade. Initial work is expected to focus on polatuzumab vedotin and teprotumumab biosimilars. Fresenius retains selection flexibility and commercialization economics; the candidate count is an option-based opportunity, not 37 approved products.

百奥赛图 / 巨潮资讯 CNinfo

Biocytogen reports nine-month revenue growth of 49.09%

Biocytogen reported consolidated revenue of RMB1.403 billion, up 49.09%, and attributable net income of RMB312.4 million for the nine months ended September 30, 2026. Attributable net income increased 173.77%. The group combines animal models, research services, and antibody licensing activities. The quarterly filing is unaudited and covers the year-to-date period.

药石科技 / 巨潮资讯 CNinfo

PharmaBlock Sciences reports nine-month revenue growth of 15.16%

PharmaBlock Sciences reported consolidated revenue of RMB1.634 billion, up 15.16%, and attributable net income of RMB151.2 million for the nine months ended September 30, 2026. Attributable net income rose 33.36%, while net cash from operations declined 53.75% over the same period. The quarterly filing is unaudited and covers the year-to-date period.

Continue your research

Explore company filters, side-by-side comparisons, private bookmarks, and member discussions.

Open free member tools ↗
AI assistant ↗